The effects of weight on adverse event reporting in Parkinson's disease patients treated with IPX066 extended-release carbidopa-levodopa capsules

被引：0

|

作者：

Kell, S.

O'Connell, M.

Hsu, A.

Silver, D.

Elmer, L.

Gupta, S.

机构：

来源：

MOVEMENT DISORDERS | 2013年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

410

引用

收藏

页码：S146 / S147

页数：2

相关论文

共 50 条

[1] The effects of gender on adverse event reporting in Parkinson's disease patients treated with IPX066 extended-release carbidopa-levodopa capsules
Kell, S.
O'Connell, M.
Hsu, A.
Silver, D.
Elmer, L.
Gupta, S.
MOVEMENT DISORDERS, 2013, 28 : S148 - S148
[2] The effects of duration of exposure on adverse event reporting in Parkinson's disease patients treated with IPX066 extended-release carbidopa-levodopa capsules
Kell, S.
Hsu, A.
O'Connell, M.
Simuni, T.
Gupta, S.
MOVEMENT DISORDERS, 2013, 28 : S148 - S149
[3] Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease
Mueller, Thomas
Moehr, Jan-Dominique
EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (18) : 2063 - 2071
[4] IPX066: a novel carbidopa-levodopa extended-release formulation
Hauser, Robert A.
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (02) : 133 - 140
[5] Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsules in Patients with Early Parkinson's Disease
Nausieda, Paul
Rudzinska, Monika
Kell, Sherron
O'Connell, Martin
Hsu, Ann
Gupta, Suneel
NEUROLOGY, 2013, 80
[6] Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson's disease patients: Dosing patterns
Morgan, J.
Stacy, M.
Rubens, R.
Khanna, S.
Gupta, S.
MOVEMENT DISORDERS, 2016, 31 : S659 - S659
[7] Efficacy and Safety of IPX066, a Carbidopa-Levodopa, Extended-Release Formulation, in Early Parkinson's Disease
Pahwa, Rajesh
Elllenbogen, Aaron
Kell, Sherron
O'Conell, Martin
Hauser, Robert
Fahn, Stanley
Jankovic, Joseph
Pourcher, Emmanuelle
Hsu, Ann
Gupta, Suneel
ANNALS OF NEUROLOGY, 2013, 74 : S47 - S47
[8] Efficacy of IPX066, an extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease patients with troublesome dyskinesia
Dhall, R.
Struck, L.
Rubens, R.
Shah, V.
Gupta, S.
MOVEMENT DISORDERS, 2015, 30 : S79 - S80
[9] Safety of IPX066, an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease
Kestenbaum, Meir
Fahn, Stanley
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (05) : 761 - 767
[10] Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease
Mao, Zhongping Lily
Modi, Nishit B.
JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (08): : 974 - 982

← 1 2 3 4 5 →